2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.34 Chemotherapy and/or Immunotherapy after Progression on Tyrosine Kinase Inhibitors in EGFR Mutant Non-Small Cell Lung Cancer Patients.

EP.12A.34 Chemotherapy and/or Immunotherapy after Progression on Tyrosine Kinase Inhibitors in EGFR Mutant Non-Small Cell Lung Cancer Patients.

Back to course

Pdf Summary

The study conducted by Maxwell Okunrobo and colleagues explores the efficacy of chemotherapy and/or immunotherapy following the progression on tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non-small cell lung cancer (mNSCLC). It analyzed data from a retrospective cohort of 229 patients who received post-TKI treatments at a community cancer center, spanning from January 2015 to October 2023. The study focused on a subset of 37 patients who fit the inclusion criteria, specifically those who had previously failed at least one targeted therapy. These patients were given either chemotherapy, immunotherapy, or a combination of both.<br /><br />The results showed that the majority (26 out of 37) received a combination of chemotherapy and immunotherapy, a strategy that yielded improved progression-free survival (PFS) and overall survival (OS) compared to those receiving single-modality treatments. This improvement was consistent with previous studies like IMpower150 and KEYNOTE 189, which also indicated enhanced outcomes with combination treatment regardless of PD-L1 status or brain metastasis presence.<br /><br />Despite these findings, the survival outcomes were not statistically significant for patients with non-EGFR mutations, likely due to a small sample size. The study was limited by its retrospective design, small sample size, and incomplete documentation. Therefore, larger studies are recommended to further examine the potential benefits of combined treatment regimens for mNSCLC patients with non-EGFR mutations.<br /><br />Overall, this research supports the integration of both chemotherapy and immunotherapy for patients whose cancer progresses on TKI treatment, highlighting the need for further investigation to confirm the benefits across broader patient groups.

Asset Subtitle

Maxwell Okunrobo

Meta Tag

Speaker Maxwell Okunrobo

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

EGFR-mutant

non-small cell lung cancer

chemotherapy

immunotherapy

tyrosine kinase inhibitors

progression-free survival

overall survival

retrospective cohort

combination treatment

mNSCLC